黑色素瘤 z-bo 2020-10-28 386

　　In the latest research report published in the international journal "Clinical Cancer Research", scientists from Edith Cowan University and other institutions have discovered important cancer blood markers through their research. This may help scientists choose the most effective melanoma treatment-related research results, and may help improve the survival rate of melanoma patients. Researchers have found that patients with high levels of ctDNA (circulating tumor DNA) may benefit from effective treatments for melanoma.

　　CtDNA is an important blood marker of cancer. Related research results can also help clinicians effectively develop new melanoma therapies. Researcher Gray said that choosing the right medicine and the treatment of melanoma is very cumbersome and complicated, and depends on a series of factors, such as tumor characteristics and systemic spread. Biomarkers can help clinicians better determine how to use combination therapy to treat which patients can achieve better results. Of course, the results in this article need more detailed research to confirm. Researchers also need to carefully consider how to use biomarkers in melanoma treatment decisions. Most importantly, you need to know when certain drugs should be used to target cancer and which patients will benefit more from active treatment. This method usually leads to more serious side effects of treatment.

　　At the same time, the research in this article will help clinicians develop personalized treatment strategies based on specific disease characteristics and patients. Researchers have found that ctDNA biomarkers may not help predict the prognosis of melanoma patients who use immunotherapy as a second-line treatment. Previous studies have shown that such biomarkers are more useful before first-line treatment. Predict the survival rate of patients. We found that ctDNA can be used to show the patient's response to the first round of targeted melanoma treatment, so the survival rate of patients after receiving second-line treatment is unpredictable. In other words, clinicians can use other treatment methods. The means to determine whether the treatment can successfully treat patients with melanoma.

　　This research is based on a scientist's investigation of cancer biomarkers in the blood (often called liquid biopsy). The study of these biomarkers is critical to understanding how cancer spreads in the body. Detailed analysis of major biomarkers. Maybe it also helps unlock more effective treatments. Researchers say they are currently looking for new drugs and therapies to treat melanoma, but if they find evidence that a specific drug acts on tumors with specific characteristics, their targeted and accurate treatments may help Improve current drug treatment methods.

　　Currently, researchers are studying the characteristics of tolerant melanoma and clarifying why the second-line treatment cannot effectively treat melanoma. In addition, the research in this paper raises many questions. Researchers want to know how it looks. This mechanism makes tumors unique and resistant to treatment.